Rockefeller University

Despite missing the primary endpoint of a Phase II trial testing solengepras (CVN424) in early, untreated Parkinson’s disease, Cerevance pointed to positive numerical trends on several key secondary e

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. MacroGenics Gets $40m Up Front For St

The approval of the first genetic medicines for sickle cell disease (SCD) on the eve of the American Society of Hematology (ASH) annual meeting set off a celebratory feel for the conference, held 9-12

Germany’s BI Licenses Tumor-Specific Antibodies From Singapore Lab Boehringer Ingelheim GmbH and Singapore’s Agency for Science, Technology and Research (A*STAR) unveiled a global licensing agreem